Alterity Therapeutics Announced That The Last Patient In ATH434-202 Phase 2 Trial Has Completed The Study Designed To Evaluate The Safety, Efficacy And Target Engagement Of ATH434 In Participants With Advanced Multiple System Atrophy, Topline Data Expecte